US Patent Issued to Nanjing Legend Biotech on April 21 for "Glypican-2-binding moieties, chimeric antigen receptors and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,635, issued on April 21, was assigned to Nanjing Legend Biotech Co. Ltd. (Nanjing, China).

"Glypican-2-binding moieties, chimeric antigen receptors and uses thereof" was invented by Wang Zhang (Nanjing, China), Jintao Guo (Nanjing, China), Fengyuan Tang (Nanjing, China), Shuai Yang (Nanjing, China), Yuanyuan Peng (Nanjing, China), An Tang (Nanjing, China), Xiaojie Tu (Nanjing, China), Yunlei Liu (Nanjing, China) and Shu Wu (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides GPC2-specific antibodies and antigen binding fragments thereof. A chimeric antigen receptor (CAR) that specifically binds glypican-2 ...